The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
Open accessAbstract
OBJECTIVES: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses. METHODS: A total of 144 consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion CFU/day (71 patients) or with placebo (73 patients). RESULTS: In all, 65 patients in the VSL#3 group and 66 patients in the placebo group completed the study. The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI)₉₅(%) 0.51-0.74; intention to treat (ITT) P=0.031, CI₉₅(%) 0.47-0.69). Significant results with VSL#3 were recorded in an improvement of three points or more in the UCDAI score (60.5% vs. 41.4%; PP P=0.017, CI₉₅(%) 0.51-0.74; ITT P=0.046, CI₉₅(%) 0.47-0.69) and in rectal bleeding (PP P=0.014, CI₉₅(%) 0.46-0.70; ITT P=0.036, CI₉₅(%) 0.41-0.65), whereas stool frequency (PP P=0.202, CI₉₅(%) 0.39-0.63; ITT P=0.229, CI₉₅(%) 0.35-0.57), physician's rate of disease activity (PP P=0.088, CI₉₅(%) 0.34-0.58; ITT P=0.168, CI₉₅(%) 0.31-0.53), and endoscopic scores (PP P=0.086, CI₉₅(%) 0.74-0.92; ITT P=0.366, CI₉₅(%) 0.66-0.86) did not show statistical differences. Remission was higher in the VSL#3 group than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI₉₅(%) 0.36-0.60; ITT P=0.132, CI₉₅(%) 0.33-0.56). Eight patients on VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects. CONCLUSIONS: VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants. Moreover, VSL#3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 8 weeks of treatment, although these parameters do not reach statistical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In IBD, the probiotic mixture VSL#3, which contains bifidobacteria of different species, was able to reduce the UC symptoms in adults (144, 145) as well as the remission of the disease in children (84).”
From Bifidobacteria and Their Health-Promoting Effects (2017) · cites this paper as [145]
In the citing paper
“Both demonstrate that high doses improve disease activity scores”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
A microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340
Kornbluth, A. A., & Sachar, D. B. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,032
Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G., Poggioli, G., Miglioli, M., & Campieri, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.9370 · Cited by 1,485
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251306 · Cited by 1,226
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Rembacken, B., Snelling, A. M., Hawkey, P. M., Chalmers, D. M., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,100
Probiotic bacteria enhance murine and human intestinal epithelial barrier function
Madsen, K., Cornish, A. S., Soper, P., McKaigney, C. J., Jijon, H. B., Yachimec, C., Doyle, J. S. G., Jewell, L. D., & Simone, C. D. (2001) · Gastroenterology · doi:10.1053/gast.2001.27224 · Cited by 1,096
Kruis, W., SCHÜTZ, E., Fric, P., Fixa, B., Judmaier, G., & Stolte, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 774
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 489
Sohail, G., Xu, X., Christman, M. C., & Tompkins, T. A. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i15.961 · Cited by 15
Parian, A. M., Mullin, G. E., Langhorst, J., & Brown, A. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00050-5 · Cited by 15
Singh, J., Sharma, M., Singh, H., Arora, P., Utreja, P., & Kumar, S. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02764-3 · Cited by 14
Meng, W., Fenton, C. G., Johnsen, K.-M., Taman, H., Florholmen, J., & Paulssen, R. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-57440-0 · Cited by 11
“The grade of inflammation was assessed during colonoscopy using the UC disease activity index (UCDAI) endoscopic sub-score with 3 to 10 for mild to moderate disease 23 .”
Zhu, Y., He, D., Gao, X., Wang, A., Yu, J., Wang, S., Cui, B., Mu, G., Ma, C., & Tuo, Y. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c13044 · Cited by 12
Clinical applications of probiotics in gastrointestinal disorders in children.
Chen, C., & Walker, W. A. (2011) · PubMed · Cited by 11
Nutritional Aspects of Pediatric Gastrointestinal Diseases
Chio, T. D., Sokollik, C., Peroni, D. G., Hart, L., Simonetti, G. D., Righini‐Grunder, F., & Borrelli, O. (2021) · Nutrients · doi:10.3390/nu13062109 · Cited by 11
“VSL#3, a multi-strain mix, induces remission in mild to moderate UC [46] and has positive effects on disease activity as adjunct therapy [47].”
BackgroundWang, X., Zhou, C., Zhang, S., Ma, Y., Xiao, W., & Guo, Y. (2024) · European Journal of Nutrition · doi:10.1007/s00394-023-03307-5 · Cited by 10
Prebiotics and Probiotics Supplementation in Pigs as a Model for Human Gut Health and Disease
Rossi, R., & Mainardi, E. (2025) · Biomolecules · doi:10.3390/biom15050665 · Cited by 17
“These results were due to the ability of probiotics to maintain the balance of the intestinal microbiota, reduce mucosal inflammation, and promote intestinal barrier function [125].”
Ince, M. N., Blazar, B. R., Edmond, M. B., Tricot, G. J. K., & Wannemuehler, M. J. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000599 · Cited by 11
“thermophilus, has been shown in preclinical colitis models and by clinical studies in IBD patients.(21,22) Additional epidemiological studies discovered higher prevalence of IBD among people with decreased frequency of infections, lending support to the hygiene hypothesis.”
BackgroundProspects of Using Microbiota Correction Methods in the Treatment of Inflammatory Bowel Disease
Akinshina, A. I., Smirnova, D. V., Zagaynova, A. V., Makarov, V. V., & Yudin, S. M. (2019) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2019-29-2-12-22 · Cited by 9
“деленных бактерий, способствующих укреплению здоровья [47, 48].”
Probiotics: are they beneficial?
Fehily, S. R., Basnayake, C., Wright, E. K., Yao, C. K., Godsell, J. D., Gibson, P. R., & Kamm, M. A. (2024) · Internal Medicine Journal · doi:10.1111/imj.16388 · Cited by 13
Lu, H.-Y., Zhang, G., Wang, K., Liu, K., Gao, Y., Chen, J.-Y., Li, Y.-X., & Yan, J.-H. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10551-0 · Cited by 8
Probiotics in IBD: Evidence and Perspectives on Patient Health and Disease Management
Hijová, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189065 · Cited by 14
“#3 were also documented in another study [88].”
Laffusa, A., Burti, C., Viganò, C., Poggi, F., Grieco, L., Occhipinti, V., Greco, S., & Orlando, S. (2025) · Biomedicines · doi:10.3390/biomedicines13112667 · Cited by 9
“By delivering defined microbial products (e.g., butyrate), postbiotics may promote epithelial integrity and regulatory immune responses, offering theoretical advantages in immunocompromised patients due to their favourable safety profile [87,89].”
InfluentialZhang, Y., Zhou, K., Chen, X., Zhang, H., Han, J., & Ning, K. (2025) · Microbiome · doi:10.1186/s40168-025-02269-6 · Cited by 9
“MicroProphet’s predictive capacity could guide the timing of fecal microbiota transplantation or probiotic administration (e.g., Lactobacillus and Bifidobacterium-based formulations) based on real-time microbial trajectory simulations [36, 37].”
Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
Puvvada, S. R., Luvsannyam, E., Patel, D. N., Hassan, Z., & Hamid, P. (2020) · Cureus · doi:10.7759/cureus.10247 · Cited by 9
Petito, V., Greco, V., Laterza, L., Graziani, C., Fanali, C., Lucchetti, D., Barbaro, M. R., Bugli, F., Pieroni, L., Lopetuso, L. R., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa298 · Cited by 10
Self-citationProbiotics and gastrointestinal diseases
Dargenio, V. N., Castellaneta, S. P., PANICO, S., Papagni, M. E., Dargenio, C., SCHETTINI, F., Francavilla, R., & Cristofori, F. (2022) · Minerva Pediatrics · doi:10.23736/s2724-5276.22.07031-8 · Cited by 10
Probiotics and fecal microbiota transplantation in surgical disorders
Yeh, A., & Morowitz, M. J. (2017) · Seminars in Colon and Rectal Surgery · doi:10.1053/j.scrs.2017.09.007 · Cited by 9
Nutritional Support and Probiotics as a Potential Treatment of IBD
Tarasiuk, A., & Eibl, G. (2020) · Current Drug Targets · doi:10.2174/1389450121666200504075519 · Cited by 9
Inflammatory Bowel Diseases and the Efficacy of Probiotics as Functional Foods
Vitetta, L., Oldfield, D., & Sali, A. (2024) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1602013 · Cited by 9
What colorectal surgeons should know about probiotics: a review
Kvasnovsky, C., Bjarnason, I., & Papagrigoriadis, S. (2015) · Colorectal Disease · doi:10.1111/codi.13046 · Cited by 8
Role of a mixed probiotic product, VSL#3, in the prevention and treatment of colorectal cancer
Wei, L., Duan, L., Zhao, H., & Tai, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175152 · Cited by 8
Pulvirenti, G., Sortino, V., Manti, S., Parisi, G. F., Papale, M. R., Giallongo, A., & Leonardi, S. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01366-8 · Cited by 8
“The authors reported the positive effect of a high-potency probiotic mixture in patients with chronic pouchitis on the duration of remission [72].”
BackgroundRemission endpoints in ulcerative colitis: A systematic review
Jitsumura, M., Kokelaar, R., & Harris, D. A. (2017) · World Journal of Meta-Analysis · doi:10.13105/wjma.v5.i4.85 · Cited by 8
Probiotics: current regulatory aspects of probiotics for use in different disease conditions
Pogačar, M. Š., Mičetić‐Turk, D., & Fijan, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823733-5.00021-0 · Cited by 9
Use of Probiotics to Prevent Celiac Disease and IBD in Pediatrics
Serena, G., & Fasano, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_317 · Cited by 8
Gravina, A. G., Pellegrino, R., Palladino, G., Imperio, G., Calabrese, F., Pasta, A., Giannini, E. G., Federico, A., & Bodini, G. (2024) · Biomolecules · doi:10.3390/biom14091164 · Cited by 8
Probiotics for ulcerative colitis: mechanisms, therapeutic advances, and emerging strategies
Niu, C., Wang, J., Lu, X., & Yu, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1787284 · Cited by 7
Intestinales Mikrobiom und chronisch-entzündliche Darmerkrankungen: Feindschaft oder Freundschaft?
Bürger, M., Lange, K. S., & Stallmach, A. (2015) · Die Gastroenterologie · doi:10.1007/s11377-014-0963-7 · Cited by 7
Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD)
Abraham, B. P., & Quigley, E. M. M. (2014) · Springer eBooks · doi:10.1007/978-3-319-26890-3_8 · Cited by 7
Fuxman, C., Sicilia, B., Linares, M. E., García‐López, S., Sueyro, R. C. G., González-Lamac, Y., Zabana, Y., Hinojosa, J., Acosta, M. B.-D., Balderramo, D. C., et al. (2023) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.01.009 · Cited by 7
Benefits of multistrain bacteria formulations for health
Laterza, L., Gibiino, G., Scaldaferri, F., & Gasbarrini, A. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.05.051 · Cited by 8
Self-citationInokuma, K., Sasaki, D., Shintani, T., Inoue, J., Oyama, K., Noda, Y., Maeda, T., Yamada, R., Matsuki, Y., Kodama, Y., et al. (2025) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-025-13424-2 · Cited by 6
“Clinical studies have shown that probiotics can reduce DAI scores in patients with relapsing mild-to-moderate UC who are under treatment with 5-aminosalicylic acid and/or immunosuppressants (Tursi et al. 2010).”
Ranjbar, M., Naeini, F., Rostamian, A., Djafarian, K., & Mohammadi, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36230 · Cited by 6
“The general mechanisms of action of probiotics target two main aspects: (a) altering the composition and function of the gut flora and (b) enhancing gut mucosal immunity, leading to anti-inflammatory responses [45].”
BackgroundBahrami, S., Babaei, N., Ghaleh, H. E. G., Borazjani, J. M., & Farzanehpour, M. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1456053 · Cited by 6
Gomollón, F., García‐López, S., Sicilia, B., Gisbert, J. P., & Hinojosa, J. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2012.11.002 · Cited by 6
Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease
Wang, X., Zhao, J., Feng, Y., Feng, Z., Ye, Y., Liu, L., Kang, G., & Cao, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.916543 · Cited by 6
“However, Visbiome® activated Treg cells (CD4+FoxP3+) and T lymphocytes to produce anti-inflammatory cytokines IL-10 and short-chain fatty acids more effectively than VSL#3, which may be due to different production methods or composition ratios of individual bacterial species (Biagioli et al., 2019).”
MethodInfluentialProbiotics, Prebiotics and Antibiotics in the Treatment of Inflammatory Bowel Disease
Calafiore, A., Gionchetti, P., Calabrese, C., Tambasco, R., Fornarini, G. S., Liguori, G., Riso, D., Campieri, M., & Rizzello, F. (2012) · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) · Cited by 6
Jiang, Y. Q., Zhang, Z., Qi, F., Zhang, Y., & Han, T. (2016) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2016.07.002 · Cited by 6
Probiotic and Prebiotic Interactions and Their Role in Maintaining Host Immunity
Sadiq, M. B., Azhar, F.-U.-A., & Ahmad, I. N. (2022) · Springer eBooks · doi:10.1007/978-981-16-1626-6_22 · Cited by 6
VSL#3 and Remission in Active Ulcerative Colitis: Larger Studies Required
Jackson, E. L., Hamlin, P. J., & Ford, A. C. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.451 · Cited by 6
Zhang, Y., Zhou, K., Chen, X., Zhang, H., Han, J., & Ning, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.08.652793 · Cited by 6
Kasapoglu, M., Yadavalli, R., Nawaz, S., Althwanay, A. M., AlEdani, E. M., Kaur, H., & Butt, S. R. (2024) · Cureus · doi:10.7759/cureus.60786 · Cited by 5
“No major safety issues arose with short-term use, but long-term adverse effects cannot be excluded, given limited follow-up durations [28,30-34].”
The Mechanisms of Immune System Regulation by Probiotics in Immune-Related Diseases
Bastani, P., Rad, A. H., Norouzi-Panahi, L., Tondhoush, A., Norouzi, S., Mehrabany, E. V., & Kasaie, Z. (2016) · Journal of Pharmacy and Nutrition Sciences · doi:10.6000/1927-5951.2016.06.03.4 · Cited by 5
Treatment of Inflammatory Bowel Disease in Ulcerative Colitis
Chibbar, R., Alahmadi, A., & Dieleman, L. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00037-9 · Cited by 5
Takahashi, R., Noguchi, T., Mizoguchi, Y., Shimoyama, T., Nakazawa, T., & Ikuta, T. (2018) · BioMed Research International · doi:10.1155/2018/9184093 · Cited by 5
Research Article Omics of probiotic bacteria: which features to seek?
Castro-Oliveira, L., Silva, M. O., Carvalho, R. D. D. O., Anchieta, A. G., Benevides, L., Oliveira, C. J. F., Jan, G., Figueiredo, H. C. P., Azevedo, V., & Soares, S. D. C. (2020) · Genetics and Molecular Research · doi:10.4238/gmr18599 · Cited by 5
“…irritable bowel syndrome, Crohn's disease and Genetics and Molecular Research 19 (2): gmr18599 ©FUNPEC-RP www.funpecrp.com.br Probiotic bacteria - omics approach 3 ulcerative colitis, in conjunction with usual medical treatments (Bibiloni et al., 2005; Sood et al., 2009; Tursi et al., 2010).”
BackgroundCentanni, M., Turroni, S., Rampelli, S., Biagi, E., Quercia, S., Consolandi, C., Severgnini, M., Brigidi, P., & Candela, M. (2014) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12515 · Cited by 5
“In particular, the use of probiotics in IBD treatment has shown encouraging results, facilitating and stabilizing clinical remission in ulcerative colitis (UC) patients (Kruis et al., 2004; Miele et al., 2009; Sood et al., 2009; Tursi et al., 2010).”
BackgroundСовалкин, В. И., Равильевна, Б. Г., & Emel’yanova, Y. A. (2017) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2017-7-4-252-259 · Cited by 5
Prebiotics, Probiotics, and Synbiotics: A Bifidobacterial View
Morelli, L., Callegari, M. L., & Patrone, V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805060-6.00017-x · Cited by 6
Pan-omics focused to Crick's central dogma
Jaiswal, A. K., Tiwari, S., Tavares, G. C., da Silva, W. M., Oliveira, L. D. C., Ibraim, I. C., Guimarães, L. C., Gomide, A. C. P., Jamal, S. B., Pantoja, Y., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817076-2.00001-9 · Cited by 5
Health Benefits of Probiotic Consumption
Bastani, P., Akbarzadeh, F., Rad, A. H., Javadi, M., & Khalili, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-25277-3_9 · Cited by 5
Gut Microbiota in IBD: The Beneficial and Adverse Effects of Diet and Medication
Juhl, A. E., Westfall, M., Jensen, B. H., & Mirsepasi‐Lauridsen, H. C. (2025) · Nutrients · doi:10.3390/nu18010009 · Cited by 4
“#3 has shown efficacy in sustaining disease remission in UC patients for more than six months [42,43], but long-term outcomes in the long-term health of UC patients remain uncertain.”
Emerging Patterns in Dietary Supplement Use Among US Adults, 1999-2023
Lam, C. S., O’Connell, K., Monroy‐Iglesias, M. J., Wang, P., Hou, Y.-N., Du, M., Giovannucci, E. L., Mao, J. J. J., & Kantor, E. D. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.19291 · Cited by 4
Supplements and diets for antiinflammation
Banu, A. T., & Lunghar, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819218-4.00007-9 · Cited by 4
Xie, Y., Zhou, L., Li, H., & Li, Y. (2021) · Current Microbiology · doi:10.1007/s00284-021-02392-1 · Cited by 4
Microbiome additive therapy for the human health
Radhakrishnan, A., Kapil, T., Kapardar, R. K., & Srivastav, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00011-2 · Cited by 4
Ng, J. Y., Liu, H., & Wang, M. C. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04062-0 · Cited by 4
“, aminosalicylic acid, immunosuppressants) was more effective in treating IBD than conventional medicine alone [9, 10, 24].”
BackgroundTamizifar, B., Feizi, A., khorasani, M. R., Kassaian, N., Zamanimoghadam, A., Arbabnia, S., & Adibi, P. (2023) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v13i11.1098 · Cited by 4
Hu, Y., Xu, C., Xu, Z., Chen, X., Gao, F., Lin, T., Yang, P., Kan, S., Yin, Y., & Chen, D. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104297 · Cited by 4
Guandalini, S. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0050-z · Cited by 4
Giacchi, V., Sciacca, P., & Betta, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00019-8 · Cited by 5
Kim, J. K., & Cheon, J. H. (2022) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2022.00031 · Cited by 4
“Patients receiving Bifidobacterium longum 536 or VSL#3 as an adjunct to standard treatment showed a significant decrease in rectal bleeding [15,16].”
BackgroundEvaluation of microbial and vancomycin treatments in ulcerative colitis in murine models
Hasan, N., & Yang, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285613 · Cited by 4
Dignass, A. U., Lindsay, J. O., Sturm, A., Windsor, A. C. J., COLOMBEL, J. ‐., Allez, M., D’Haens, G., D’Hoore, A., Mantzanaris, G., Novacek, G., et al. (2015) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2014.10.007 · Cited by 4
Guarner, F. (2011) · Colloquium Series on Integrated Systems Physiology From Molecule to Function · doi:10.4199/c00047ed1v01y201110isp029 · Cited by 4
Probiotics for Gastrointestinal Diseases
Akpınar, H. (2013) · CRC Press eBooks · doi:10.1201/b15561-16 · Cited by 4
Chinese consensus on the prevention of colorectal cancer (2016, S hanghai)
Fang, J., Yong Quan, S. H. I., Chen, Y., Li, J., & Sheng, J. Q. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12450 · Cited by 4
Meyer, J., Röös, E., Ris, F., Fearnhead, N. S., & Davies, J. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104446 · Cited by 4
Rosali, M. I., Velu, D. P. V. T., Mokhtar, M. H., Ali, R. A. R., Mokhtar, N. M., & Hamid, A. A. (2026) · Biomedicines · doi:10.3390/biomedicines14061386 · Cited by 3
“#3 is one of the high-complexity MSPs that has been consistently studied for its efficacy and safety in UC treatment [75–78].”
Herbal Medicines for the Management of Irritable Bowel Syndrome and Constipation Problem
Puppala, E. R., Prasad, N., Singh, M., Prakash, A. N., Abubakar, M., Adhikari, P., & Naidu, V. G. M. (2023) · Springer eBooks · doi:10.1007/978-981-99-7703-1_16 · Cited by 3
Functional Evaluation Model for Lactic Acid Bacteria
Zhai, Q., & Chen, W. (2019) · Springer eBooks · doi:10.1007/978-981-13-7832-4_7 · Cited by 3
The human microbiota and its therapeutic options
Chen, Y., & Li, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00056-3 · Cited by 3
Corbetta, P., Lonati, E., Pagliari, S., Mauri, M., Cazzaniga, E., Botto, L., Campone, L., Palestini, P., & Bulbarelli, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147869 · Cited by 3
“In addition, probiotic supplementation in combination with traditional medicine is effective in IBD treatment [11].”
BackgroundProbiotics to Prevent Celiac Disease and Inflammatory Bowel Diseases
Fasano, A., & Matera, M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-58572-2_6 · Cited by 4
Quraishi, M. N., Moakes, C. A., Yalchin, M., Segal, J. P., Ives, N. J., Magill, L., Manzoor, S. E., Gerasimidis, K., Loi, S., McMullan, C., et al. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/ycjd4579 · Cited by 5
Ulcerative Colitis in Children and Adolescents
Andrew, S. L., & Daniel, A. (2011) · InTech eBooks · doi:10.5772/26743 · Cited by 3
Picco, M. F. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00331-2 · Cited by 3
Microbiome and Diseases: Inflammatory Bowel Diseases
Hildner, K., Waldschmitt, N., & Haller, D. (2018) · Springer eBooks · doi:10.1007/978-3-319-90545-7_11 · Cited by 3
Probiotics in the Complex Treatment of Various Diseases of the Gastrointestinal Tract
Ivashkin, K., Reshetova, M., Zolnikova, O., Korneev, V. R., & Shirokova, E. (2020) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2020-30-1-42-48 · Cited by 1
Zalila‐Kolsi, I., & Al-Barazie, R. (2026) · Biology · doi:10.3390/biology15090665 · Cited by 2
“#3 significantly reduced disease activity as adjunctive therapy in relapsing mild-to-moderate disease [17], as well as a large double-blind, double-dummy trial showing that Escherichia coli Nissle 1917 was equivalent to mesalazine in maintaining remission over 12 months [18].”
Suadoni, M. T. (2013) · Journal of Radiotherapy in Practice · doi:10.1017/s1460396913000198 · Cited by 2
Intestinal Microbiology and Ecology in Crohn’s Disease and Ulcerative Colitis
Buttó, L. F., & Haller, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-33703-6_4 · Cited by 2
Tsuruda, C. T., de Souza, P. C., Nishio, E. K., Almeida, R. S., Panagio, L. A., Baptista, A. A. S., García, S., Pinheiro, D. O., Araújo, E. J. D. A., Chue-Gonçalves, M., et al. (2020) · Microbiology Research Journal International · doi:10.9734/mrji/2020/v30i730238 · Cited by 2
“Besides these positive effects, probiotics are useful for prevention and treatment of gastrointestinal diseases, such as irritable bowel syndrome [7], inflammatory bowel disease [8],”
The authenticity of probiotic foods and dietary supplements: facts and reflections from a court case
Simone, C. D. (2022) · CyTA - Journal of Food · doi:10.1080/19476337.2022.2141344 · Cited by 2
“…formulation (Bibiloni et al., 2005; Gionchetti et al., 2000, 2003; Huynh et al., 2009; Karimi et al., 2005; Kuhbacher et al., 2006; Lee et al., 2012; Miele et al., 2009; Mimura et al., 2004; Ng et al., 2010; Pronio et al., 2008; Sood et al., 2009; Tursi et al., 2004, 2010; Ulisse et al., 2001).”
Therapeutic Effects of Zymomonas mobilis on Experimental DSS-Induced Colitis Mouse Model
do Almo, M. M., Sousa, I. G., Olinto, V. G., Pinhate, S. B., Jivago, J. L. D. P. R., de Sousa, D. E. R., de Castro, M. B., Rubini, M. R., Maranhão, A. Q., & Brígido, M. M. (2023) · Microorganisms · doi:10.3390/microorganisms11112793 · Cited by 2
“This medication proved to be safe and effective in reducing the symptoms caused by UC, in addition to inducing and maintaining remission of this disease for a period in the patients tested [35–37].”
BackgroundMicrobiota, Prebiotics, Antibiotics and Fecal Microbiota Transfer
Nörenberg, J., Vogler, S., & Stallmach, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-75022-4_14 · Cited by 1
Probiotics: A Mainstream Therapy for the Disease Suppression
Ghattargi, V. C., Shouche, Y. S., Dhakephalkar, P. K., Rao, P. K., Ramana, V., Dhotre, D. P., & Lanjekar, V. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00008-5 · Cited by 2
Gene–environment interactions in inflammatory bowel disease: microbiota and genes
Aldhous, M. C. (2012) · Frontline Gastroenterology · doi:10.1136/flgastro-2011-100097 · Cited by 2
Clinical Insights: Probiotics, Prebiotics and Gut Health
Floch, M. H., & Kim, A. S. (2014) · doi:10.2217/9781780843360 · Cited by 2
Nutritional Management of Inflammatory Bowel Disease and Short Bowel Syndrome
Barnes, J. L., & Tappenden, K. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391884-0.00039-1 · Cited by 3
Lactic Acid Bacteria and Gut Health
Li, H., & Fang, Z. (2019) · Springer eBooks · doi:10.1007/978-981-13-7832-4_8 · Cited by 2
Probiotics and intestinal health
Guslandi, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85170-1.00013-0 · Cited by 2
Nutritional Management of Inflammatory Bowel Disease and Short Bowel Syndrome
Barnes, J. L., & Tappenden, K. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00039-4 · Cited by 2
Tursi, A., & Papa, A. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.452 · Cited by 2
Self-citationAn Overview of Probiotic Research
Ζουμποπούλου, Γ., Tsakalidou, E., & Thomas, L. V. (2017) · Wiley eBooks · doi:10.1002/9781119214137.ch8 · Cited by 3
Garavaglia, B., Vallino, L., Amoruso, A., Pane, M., Ferraresi, A., & Isidoro, C. (2023) · Preprints.org · doi:10.20944/preprints202312.1804.v1 · Cited by 1
Metadata
- Authors
- Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., Modeo, M. E., Rodino', S., D'Amico, T., Sebkova, L., Sacca', N., Di Giulio, E., Luzza, F., Imeneo, M., Larussa, T., Di Rosa, S., Annese, V., Danese, S., & Gasbarrini, A.
- Affiliations
- Ospedale L. Bonomo (IT)
- Ospedale Cristo Re (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Ospedaliera Pugliese Ciaccio (IT)
- St. Eugenio Hospital (IT)
- Ospedale Santa Maria Goretti (IT)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Azienda Ospedaliero-Universitaria "Renato Dulbecco" (IT)
- Casa Sollievo della Sofferenza (IT)
- Corresponding author
- Tursi, Antonio
- ORCID
- Venue
- American Journal of Gastroenterology
- Published
- 2010-10
- Volume
- 105
- Issue
- 10
- Pages
- 2218-2227
- ISSN
- 0002-9270 (ISSN-L)
- PMC
- PMC3180711
- OpenAlex
- W1998335236
- Cited by
- 489
- References
- 39
- Citations by year
- 2026: 10 · 2025: 22 · 2024: 35 · 2023: 30 · 2022: 29 · 2021: 28 · 2020: 46 · 2019: 31 · 2018: 39 · 2017: 38 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 27 · 2012: 28
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (unspecified)
- Locations
- The American Journal of Gastroenterology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- ulcerative colitis, VSL#3, probiotics, adjunctive therapy, relapsing disease, 5-aminosalicylic acid, immunosuppressants, disease activity, rectal bleeding, stool frequency, inflammatory bowel disease treatment, pouchitis, Crohn's disease, irritable bowel syndrome, irritable bowel syndrome with diarrhea
- MeSH terms
- Adult, Azathioprine, Bifidobacterium, Colitis, Ulcerative, Combined Modality Therapy, Double-Blind Method, Female, Humans, Lactobacillus, Male, Middle Aged, Recurrence, Remission Induction, Severity of Illness Index, Treatment Outcome, Patient Selection, Mesalamine, Probiotics, Streptococcus thermophilus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
